第55届美国血液学年会骨髓增生异常综合征研究领域新进展——骨髓增生异常综合征（MDS）预后模型的评述

New progress of myelodysplastic syndromes in the 55th ASH annual meeting on prognostic models of myeledysplastic syndromes

介绍第55届美国血液学会（ASH）年会有关骨髓增生异常综合征（MDS）研究领域对预后模型的评价和展望.[PSS仍是目前最具有临床指导作用、应用也最为广泛的预后模型,但其缺失细胞遗传学和突变的相关变量,这在一定程度上限制了它作用的发挥.其他预后指标包括血清乳酸脱氢酶（LDH）、体力状态、血清铁蛋白、BM纤维化、β2微球蛋白和流式细胞分析,但目前这些指标还不具备临床预后指导价值.

New progress of myelodysplastic syndomes（MDS） in the 55th ASH annual meeting on prognostic models were reviewed.The widespread adoption of the IPSS helped improve the clinical care of patients with MDS and spurred the development of newer prognostic models to refine risk stratification.However,none has yet reached the level of the adoption enjoyed by the IPSS.Mutation testing is becoming more widely available and may eventually help with diagnosis,subtype classification,and even the prediction of therapeutic response the way it has in AML and MPNs.